Trial Profile
Phase II Trial of Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Gemcitabine (Primary)
- Indications Leiomyosarcoma
- Focus Therapeutic Use
- Acronyms EAGLES
- 24 Oct 2023 Results (n=38; between October 2018 and May 2022) assessing the efficacy and safety of avelumab plus gemcitabine in patients with leiomyosarcoma who failed first-line chemotherapy, presented at the 48th European Society for Medical Oncology Congress.
- 02 Feb 2021 Planned End Date changed from 28 Feb 2022 to 31 Dec 2022.
- 02 Feb 2021 Planned primary completion date changed from 30 Sep 2021 to 31 Dec 2021.